icon- folder.gif   Conference Reports for NATAP  
 
  Conference on Retroviruses
and Opportunistic Infections
Denver, Colorado
March 3-6 2024
 		Back grey_arrow_rt.gif
 
 
 
New HIV Therapies, Drugs at CROI 2024
 
 
 
  • CROI: Preclinical Characterization of GS-5894, a Potent NNRTI With Once Weekly Oral Dosing Potential - (03/26/24)
     
    • Case Series Examining the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial - (04/03/24)
     
    Phase 2 Study of Switch to Daily BIC + LEN in Individuals on a Complex HIV Treatment Regimen - (03/04/24)
     
    Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study - (03/06/24)
     
    Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1 - (03/06/24)
     
    Safety and Pharmacokinetics of MK-8527, a Novel nRTTI, in Adults Without HIV - (03/06/24)
     
    Lenacapavir Plus bNAbs for People with HIV and Susceptibility to Either Teropavimab or Zinlirvimab - (03/06/24)
     
    Phase 1 Study of Cabotegravir Long-Acting Injectable Formulations Supports ≥4-Monthly Dose Interval - (03/06/24)
     
    Lenacapavir Efficacy in CAPELLA Patients with No Fully Active Agents in Optimized Background Regimen - (03/04/24)
     
    VH3810109 (N6LS) in Antiretroviral Therapy-Naive Adults With HIV-1: Phase 2a BANNER Efficacy Data - (03/06/24)
     
    The Preclinical Profile of Maturation Inhibitor VH3739937 - (03/04/24)
     
    Next-Generation Maturation Inhibitor GSK3640254 Showed Broad Spectrum Potency Without MI Resistance - (03/04/24)
     
    Discovery of GS-9770 - a Novel, Unboosted, Once Daily Oral HIV-Protease Inhibitor - (03/04/24)
     
    ABBV-382, an Anti-a4b7 Ab That Enhances HIV-1 Antigen Presentation for Immune-Mediated Viral Control - (03/06/24)
     
    Biomarker Signatures in Phase Ib Study With PD-1 Inhibitor, Budigalimab, in PLWH Undergoing ATI - (03/06/24)
     
    Antiviral Activity, Safety, and Pharmacokinetics of GS-1720, a Novel Weekly Oral INSTI - (03/06/24)
     
    A First-in-Human Study of the Trispecific HIV-1 Broadly Neutralizing Antibody, SAR441236 - (03/06/24)
     
    Trispecific bNAb Hits 3 Targets but Has Modest Antiviral Activity in First Human Studies - Mark Mascolini - (03/06/24)
     
    Safety and Efficacy of VRC07-523LS Plus Long-Acting Cabotegravir in the Phase II ACTG A5357 Trial - (03/06/24)